Literature DB >> 3480060

Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.

K Vinzenz1, M Matejka, G Watzek, H Porteder, N Neuhold, M Micksche.   

Abstract

The influence of preoperative perilesional therapy with the potent bacterial biological response modifier (BRM) OK-432 on natural killer (NK) cell activity in peripheral blood and tumor draining lymph nodes (LNs) of patients with head and neck cancer (HNC) has been investigated. Pretreatment NK activity in peripheral blood (PB) was comparable within the group of HNC patients. However, after perilesional OK-432 therapy, a significant increase in cytotoxicity was observed by day 8. Furthermore, postoperative suppression of PB NK activity was less pronounced in patients with OK-432 therapy. In tumor draining LNs, NK activity was significantly higher in patients receiving OK-432 therapy than in those treated by surgery alone. No differences were detected concerning the in vitro stimulatory capacity of interferon (IFN) and/or Staphylococcus protein A (SPA) on LN NK activity in both the OK-432 treated and untreated group. Furthermore, by immunoperoxidase technique, LNs of OK-432 treated patients were found to express a higher number of cells reacting with the monoclonal antibody HNK-1 compared to LNs of the untreated group. Both these results suggest that perilesional OK-432 therapy leads to an increase in number and function of NK cells in regional LNs, together with an increase in NK activity in PB in some but not all patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3480060

Source DB:  PubMed          Journal:  Cancer Detect Prev Suppl        ISSN: 1043-6995


  2 in total

1.  Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.

Authors:  H Fukui; C W Reynolds; B Lenz; M Schneider; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Responses of killer cells in head and neck cancer patients.

Authors:  S Fujieda; H Saito; T Hoshino
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.